Akèy › Twoub depresif rezistan a tretman
Etid klinik pou Twoub depresif rezistan a tretman ap rekrite nan Etazini
33 etid pou Twoub depresif rezistan a tretman ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- San Diego, CA10 etid
- New York City, NY8 etid
- Houston, TX6 etid
- Atlanta, GA5 etid
- St. Louis, MO5 etid
- Dallas, TX4 etid
- Tampa, FL4 etid
- Austin, TX4 etid
- Washington, DC3 etid
- Philadelphia, PA3 etid
- Birmingham, AL3 etid
- Columbus, OH3 etid
- Chicago, IL3 etid
- Boston, MA3 etid
- Minneapolis, MN3 etid
- Indianapolis, IN3 etid
- O'Fallon, MO3 etid
- Baltimore, MD3 etid
- Bellevue, WA3 etid
- Queens, NY3 etid
Pa eta
- Alabama3 etid
- Arizona3 etid
- Florid5 etid
- Georgia6 etid
- Illinois4 etid
- Indiana3 etid
- Kalifòni12 etid
- Maryland6 etid
- Massachusetts7 etid
- Minnesota5 etid
- Missouri7 etid
- New York11 etid
- Ohio5 etid
- Pennsylvania3 etid
- Texas9 etid
- Utah3 etid
- Washington4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Long-term Observation of Participants With Mood Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou Oct 1, 2026 · NCT04877977Natural History of Depression, Bipolar Disorder and Suicide Risk
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 1, 2026 · NCT06462196Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
Ap rekrite
Laj 22 a 85 · Tout sèks · Mizajou Sep 29, 2026 · NCT07594483A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07716098Biomarker-Guided Antidepressant Selection
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 23, 2026 · NCT07680140DBS for TRD With the Medtronic Percept PC
Ap rekrite
Laj 25 a 70 · Tout sèks · Mizajou Sep 22, 2026 · NCT05773755Lumateperone for Late-Life Depression
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07623135Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Ap rekriteFaz 1Volontè an sante akeyi
Laj 21 a 45 · Tout sèks · Mizajou Sep 15, 2026 · NCT06480201Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
Ap rekrite
Laj 18 a 85 · Tout sèks · Mizajou Sep 15, 2026 · NCT07217223ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07284667DBS for Depression
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT06096207Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 14, 2026 · NCT06511908One-Day cTBS Over the Precuneus
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07758010PCS in Severe Treatment Resistant Depression
Ap rekrite
Laj 22 a 70 · Tout sèks · Mizajou Sep 1, 2026 · NCT04124341Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Ap rekrite
Laj 22 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06423430Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT07563868Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression
Ap rekrite
Laj 21 a 70 · Tout sèks · Mizajou Jul 15, 2026 · NCT03952962A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 15, 2026 · NCT03887715A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou May 11, 2026 · NCT06524830Mindfulness Engaged Neurostimulation for Depression (MEND II)
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou May 6, 2026 · NCT07512284NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Apr 29, 2026 · NCT02994433Maintenance rTMS for Depression (Maitr-De)
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Apr 29, 2026 · NCT06938841ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 28, 2026 · NCT07553637ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 14, 2026 · NCT07528014Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy
Ap rekriteEtid obsèvasyon
Laj 21 a 65 · Tout sèks · Mizajou Mar 12, 2026 · NCT05905705Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.